ClinicalTrials.gg

Program

alixorexton

Also written as “ALKS 2680 Dose 1”, “ALKS 2680 Dose 2” and “ALKS 2680”.

Its studies are mostly in Narcolepsy · Idiopathic Hypersomnia · Sleep Wake Disorders · Sleepiness, led by Alkermes.

Furthest: phase 3, since Jan 6, 20257 company-led studies, 5 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Alkermes75 open or runningphase 3since Jan 6, 2025Apr 2, 2024Nov 2026phase 2 · NCT06843590

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 2, 2024First study: phase 2 study in NarcolepsyFirst studyNCT06358950 · 92 enrolled · United States, Australia, Belgium and more
  2. Aug 13, 2024Phase 2 study in NarcolepsyNCT06555783 · 93 enrolled · United States, Australia, Belgium and more
  3. Jan 6, 2025Phase 3 study in Idiopathic HypersomniaNCT06767683 · 786 planned · United States, Australia, Belgium and more
  4. Feb 21, 2025Phase 2 study in Idiopathic HypersomniaNCT06843590 · 126 enrolled · United States, Australia, Belgium and more
  5. Mar 3, 20262 phase 3 studiesNCT07455383, NCT07502443
  6. Apr 15, 2026Phase 3 study in SleepinessNCT07540897 · 150 planned · United States, Belgium, Canada and more
  7. Oct 9, 2026Primary completion moved from 2028-06 to 2030-06Date moved laterphase 3 · +24 months · NCT06767683

Ahead

  1. Nov 2026Primary completion: phase 2 study in Idiopathic HypersomniaNCT06843590
  2. May 2027Primary completion: phase 3 study in Sleep Wake DisordersNCT07502443
  3. May 2027Primary completion: phase 3 study in NarcolepsyNCT07455383
  4. Jun 2027Primary completion: phase 3 study in SleepinessNCT07540897

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07540897Sleepiness · United States, Belgium, Canada and more3RecruitingJun 2027150
NCT07502443Sleep Wake Disorders · United States, Australia, Belgium and more3RecruitingMay 2027176
NCT07455383Narcolepsy · United States, Australia, Belgium and more3RecruitingMay 2027150
NCT06843590Idiopathic Hypersomnia · United States, Australia, Belgium and more2Active, not recruitingNov 2026126
NCT06767683Idiopathic Hypersomnia · United States, Australia, Belgium and more3RecruitingJun 2030786
NCT06555783Narcolepsy · United States, Australia, Belgium and more2CompletedNov 11, 202593
NCT06358950Narcolepsy · United States, Australia, Belgium and more2CompletedJun 19, 202592

How it is read

Names in the registry

  • “ALKS 2680 Dose 1”, 3 entries
  • “ALKS 2680 Dose 2”, 3 entries
  • “ALKS 2680”, 3 entries
  • “ALKS 2680, 4mg”, 1 entry
  • “ALKS 2680, 6mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.